The ANVISA Decision Most Manufacturers Get Wrong (And Why It Matters More Than You Think)

You know what we've seen happen over and over in 30 years? Manufacturers get everything right—documentation perfect, team solid, timing planned down to the week. And they still hit a wall.

It's not the obvious stuff that trips them up. Not missing paperwork or unrealistic timelines. It's an assumption they make before they even start the process. An assumption that seems so reasonable, so logical, that questioning it feels unnecessary.

Here it is: they assume their product's ANVISA classification will match what they know from FDA or Europe. Class II in the US? Should be Class II equivalent in Brazil, right? Same device, same risk profile, same regulatory tier.

Except ANVISA doesn't see it that way. Not always.

And that gap—between what manufacturers expect and what ANVISA determines—creates problems that compound for months. Sometimes years.

The Assumption That Creates Problems

Here's the pattern. We've handled more than 2,600 product registrations over three decades—100% approval rate through 2025, by the way—and the pattern is clear.

A company knows their product. Really knows it. They understand the regulatory profile in markets they've already conquered. FDA approved? Check. CE mark? Done. When Brazil comes up, they just... project forward.

"We're Class II in the US, so we'll be Class II here. The process should be similar. We can use most of the same documentation. No surprises."

Makes perfect sense, right?

Except it's built on an assumption about regulatory harmonization that doesn't fully exist. ANVISA uses risk-based classification, sure—like FDA, like Europe. But here's where it gets interesting: they interpret and apply that risk framework differently. The weights shift. The factors that matter most? Not always the same ones.

"Classification in Brazil isn't just about risk—it's about regulatory pathway, economic structure, and where you'll land in the market."

So a device that's clearly Class II under FDA's rules might land somewhere else under ANVISA's interpretation. Not because either system is wrong. They just see the same device through different lenses.

Why This Matters More Than Getting It "Right"

Here's the thing: figuring out your actual ANVISA classification isn't rocket science. You can get that answer. But by the time most manufacturers ask the question seriously, they've already made commitments based on what they assumed the answer would be.

They've built business plans. Set pricing with distributors. Made promises to partners. Allocated budget.

And then the real classification comes back different.

Now what? Admit the foundation was wrong? Rework everything? Try to absorb the impact and hope it works out?

None of those options are fun. All of them exist because classification got treated as a technical detail instead of a strategic decision.

Why Classification Determines Everything

Working with 600+ manufacturers over the years, you start to see where the big leverage points are. Where one decision ripples through everything else.

Classification is one of those points. Maybe the biggest.

Not because it's complicated—ANVISA's framework makes sense once you understand it. But because manufacturers consistently underestimate how much flows from this one determination.

Regulatory Pathway and Requirements

Different classifications trigger different pathways. Different documentation requirements. Different review processes.

Obvious in theory, right?

In practice? A device classified one way might need clinical data you didn't collect (because you didn't need it anywhere else). The same device classified differently might require technical reports structured in ways that don't match your FDA submissions—not just format changes, but fundamentally different evidence.

We've seen manufacturers show up with comprehensive submission packages, everything prepared based on their home market classification. Then ANVISA's classification comes back and none of it fits. The structure's wrong. The evidence addresses different questions. Back to square one.

Economic Implications Nobody Sees Coming

Here's what catches people off guard: classification shapes your economics in Brazil.

The fees vary by class. Renewal requirements differ. Ongoing compliance obligations shift. Post-market surveillance expectations change. It all adds up—not to rounding errors, but to material cost differences that affect whether your pricing strategy actually works.

Last year we worked with a manufacturer who'd built their Brazilian pricing model assuming Class II economics. Made sense—that's what they were everywhere else. Turned out ANVISA classified them differently. The compliance costs in their actual class made their planned pricing completely uncompetitive. They either had to eat margin or renegotiate with distributors (who weren't thrilled about either option).

Competitive Positioning

And here's the part most manufacturers miss completely.

Classification affects how hospitals see your product. Not just what you are, but how you're positioned relative to competitors. Two similar devices with different classifications? They face different market dynamics—not because the products are different, but because the regulatory profiles signal different things.

Hospital procurement teams know ANVISA classifications. They understand what different classes mean for regulatory scrutiny, for compliance burden, for long-term stability. They factor this into decisions alongside technical specs.

Get classified differently than you expected and you might find yourself competing in a different market segment than you planned for. Different price expectations. Different competitive set. Different buyer requirements.

We've seen it derail market entry strategies more than once.

The Cascading Consequences

The thing about classification errors? They don't stay isolated.

You don't just fix the classification and move on. By the time you realize it's wrong, you've made decisions—commitments, really—based on the assumption it was right. And now those decisions don't work anymore.

Timeline Disruption

Here's what happens. You plan market entry around expected approval timelines. Those timelines depend on classification—heavily. Wrong classification means wrong timeline.

But it's not just about delay. It's about all the things coordinated around that original timeline.

Distributors expecting product by certain dates. Marketing investments timed to launch windows. Trade show commitments. Partnership agreements with delivery expectations. All of it scheduled around a timeline that turns out to be based on incorrect assumptions.

Adjusting all these moving pieces mid-process? That operational complexity often exceeds the regulatory complexity you're trying to solve.

Cost Structure Mismatch

Classification determines costs. Not just registration fees—though those vary. The whole ongoing burden of maintaining ANVISA compliance. Renewals. Post-market surveillance. All the administrative overhead.

Different classes, different cost structures.

Manufacturers testing Brazil cautiously, operating on tight margins? Discovering actual costs exceed budget by meaningful percentages can shift the whole project's viability. We've seen companies scale back their Brazilian ambitions not because the market disappointed—because their cost assumptions were wrong.

Strategic Inflexibility

This one only becomes apparent over time.

Your regulatory pathway—determined by classification—constrains what you can do later. Product modifications? Label changes? Market adaptations based on feedback? All of it gets harder or easier depending on which pathway you're on.

Manufacturers who assumed one classification discover their ability to respond to market pressure is limited by regulatory constraints they didn't see coming. And by the time these limitations become clear, they've already invested significantly in the Brazilian presence.

"Classification isn't a regulatory detail. It's the foundation that determines what's possible in your Brazil strategy."

Patterns We've Seen Over Three Decades

Thirty years gives you perspective. You start seeing patterns in how companies approach classification, where things go wrong, what separates success from struggle.

The Passive Classification Approach

Most manufacturers don't actively decide their ANVISA classification. They assume it.

They know their FDA class, their CE mark tier. They project that onto Brazil without rigorous analysis of how ANVISA's specific framework applies to their specific product. It's not laziness—it's just that the assumption seems so reasonable that questioning it feels unnecessary.

When ANVISA's classification aligns with expectations? Great, no problem.

When it doesn't? Manufacturers discover the mismatch deep into regulatory submissions. Too late to adjust strategy without serious disruption.

The Technical Focus Without Commercial Context

Some companies do engage with classification early. But they treat it as a purely technical regulatory question.

"What class will ANVISA assign our product?"

They get the answer. Move on.

What they miss: the strategic dimension. The more valuable question isn't just what class you'll be—it's what different classifications would mean for your commercial strategy. How should that inform your market entry approach?

Technical understanding without strategic thinking doesn't prevent problems.

The Reclassification Dilemma

Occasionally—not often, but it happens—manufacturers discover mid-process that their product might qualify for different classification than they're pursuing.

Now they're stuck.

Continue with current pathway despite suboptimal classification? Or restart with proper classification but lose time and momentum?

Neither option is attractive. Both exist only because classification wasn't properly evaluated before committing to a path.

The manufacturers who avoid this? They invested in understanding classification implications before making strategic commitments.

Questions Worth Asking

So where does this leave you?

Probably with more questions than answers. Which is fine—classification isn't simple, and anyone who tells you otherwise is selling something.

But here are the questions that actually matter. Not the obvious ones about what class your product will be, but the strategic ones about what that means for your approach.

On Classification Determination

How confident are you in your classification assumption?

If you're projecting from FDA or EU without Brazil-specific analysis, you're building strategy on uncertain foundations. Maybe that's acceptable risk for your situation—test market, limited commitment, easy to adjust if needed. Or maybe it's not.

What would it mean if your product classified differently?

Walk through the scenarios. Different pathway means what for timeline? For costs? For your distributor agreements? Understanding the implications helps you evaluate whether additional classification analysis is worth it.

Where does your product sit on the classification spectrum?

Some devices clearly fit specific classes. Black and white, no ambiguity. Others involve regulatory interpretation. If yours is in the gray zone, classification risk is higher.

On Strategic Implications

How does classification affect your commercial model?

Different pathways create different cost structures. Run the numbers. How much would a classification difference shift your margin assumptions? Your pricing strategy? Your timeline to profitability?

What flexibility do you need?

Some classifications make product modifications and market adaptations easier. Others create more friction. Your need for flexibility should inform how you think about classification trade-offs.

How does your classification position you competitively?

Look at competing products. Their classifications. How does yours compare? What does that mean for market dynamics?

On Risk and Timing

When does classification uncertainty become too risky?

Different companies have different risk tolerances. Some can proceed with assumptions and adjust if needed—they have the resources, the flexibility, the risk appetite. Others need certainty before committing. Where do you sit?

What's the cost of getting it wrong versus getting it right upfront?

Sometimes the smartest investment is professional classification evaluation before building detailed market entry plans. Sometimes you can reasonably proceed with higher uncertainty. Depends entirely on your specific situation.

Why Companies Miss This

If classification matters this much, why do manufacturers consistently underinvest in understanding it?

Few reasons.

First, classification analysis requires Brazil-specific regulatory expertise most companies don't have in-house. It's technical, specialized—easy to delegate to consultants rather than engage with strategically.

Second, the question comes up early in market evaluation, before companies have deep Brazil engagement. It's tempting to assume classification works like familiar markets and move on to seemingly more important questions—finding distributors, understanding hospital procurement, building relationships.

Third—and this is the big one—classification seems like an obscure technical detail. Not the kind of thing CEOs or commercial teams worry about. Just a regulatory box to check.

By the time manufacturers understand Brazil well enough to appreciate classification's strategic importance, they've often committed to approaches based on classification assumptions that don't hold.

The companies we've seen succeed long-term? They recognized classification as strategic from the start. Worth understanding thoroughly even when it seemed technical and obscure.

The ones who struggled discovered classification's importance through painful experience.

Making This Decision Strategically

Look, classification in ANVISA's framework isn't just regulatory compliance. It's about understanding how your product gets positioned within Brazil's regulatory and commercial landscape.

Companies that treat it as a strategic question (not a technical checkbox) tend to make better decisions about market entry. They don't necessarily pursue different classifications—but they build strategies that account for classification realities instead of assumptions.

And you don't need to become an ANVISA classification expert to do this. You just need to recognize that classification assumptions carry risk. And that risk should be evaluated explicitly, not accepted passively.

The critical questions aren't about mechanics. They're about fit:

How confident are you in your classification assumptions? What would it mean if they're wrong? How much does classification uncertainty affect your Brazil risk profile? When does reducing that uncertainty become more valuable than moving quickly?

No standard answers to those questions. Every manufacturer in every situation will make different trade-offs. What matters is making them consciously rather than discovering them through experience.

Medical Distributors Brazil is part of BRISA Advisors. We've specialized in ANVISA regulatory strategy since 1995, working with 600+ manufacturers who value strategic thinking over template solutions.